Company news
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) news
Every Kyverna Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kyverna Therapeutics to Present at Upcoming Investor Conferences
September 2, 2026
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
August 11, 2026
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
July 27, 2026
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-S...
June 22, 2026
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, T...
June 3, 2026
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
May 18, 2026
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
May 12, 2026
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
May 4, 2026
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Dura...
April 21, 2026
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses thro...
April 20, 2026
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
April 9, 2026
The Oncology Institute Names Minh Merchant Chief Legal Officer
April 6, 2026
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 26, 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
March 5, 2026
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
March 3, 2026
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
February 24, 2026
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 3, 2026
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
January 12, 2026
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
January 5, 2026
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
December 17, 2025
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
December 15, 2025
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
December 15, 2025
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
December 14, 2025
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
November 10, 2025
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
November 3, 2025
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
October 29, 2025
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presente...
October 25, 2025
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
October 22, 2025
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Pre...
September 24, 2025
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
September 15, 2025
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual K...
August 28, 2025
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
August 25, 2025
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 12, 2025
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
August 1, 2025
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
July 29, 2025
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
June 30, 2025
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2025
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
May 13, 2025
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 27, 2025
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 3, 2025
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
January 21, 2025
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
January 6, 2025
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
December 13, 2024
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Co...
November 14, 2024
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
October 21, 2024
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at E...
September 18, 2024
Kyverna Therapeutics Announces Leadership Update
September 16, 2024